In a burn patient with leg and hand burns sustained three days ago who is receiving meropenem 1 g IV twice daily and now has a high‑grade evening fever, how should the fever and possible infection be managed?

Management of Persistent Fever in a Burn Patient on Meropenem

In a burn patient with persistent high-grade evening fever despite 3 days of meropenem 1 g twice daily, you should immediately reassess for undrained infection sources, obtain blood and wound cultures, consider increasing meropenem to 1 g every 8 hours (three times daily), and add empiric antifungal therapy if fever persists beyond 5-7 days with no identified bacterial source. 1

Immediate Assessment and Diagnostic Workup

Perform urgent source control evaluation including:

• Meticulous examination of all burn wounds for signs of necrotizing infection, purulent drainage, or progression 1
• Obtain blood cultures (at least two sets) and deep wound cultures or biopsies before any antibiotic changes 1
• Consider imaging (CT or ultrasound) to identify undrained fluid collections or deep tissue involvement 1
• Evaluate vascular access sites for catheter-related infection 1

The median time to defervescence in high-risk patients is 5-7 days, so persistent fever at day 3 alone does not mandate antibiotic change if the patient is clinically stable 1. However, evening fever patterns and clinical deterioration require immediate action 1.

Antibiotic Optimization

Meropenem Dosing Correction

Your current meropenem dose of 1 g twice daily is inadequate. The FDA-approved dosing for complicated skin and soft tissue infections is:

• Standard dose: 500 mg every 8 hours 2
• For Pseudomonas coverage: 1 g every 8 hours 2

Burn patients require higher and more frequent dosing due to:

• Increased volume of distribution (up to 44.4 L vs. normal 17-28 L) 3, 4
• Enhanced renal clearance (mean 19.0 L/h) 3
• Significantly altered pharmacokinetics that reduce drug concentrations 5, 4, 6

Recommended adjustment: Increase to 1-2 g every 8 hours given as extended infusion over 3 hours to achieve adequate time above MIC 5, 4. Standard 30-minute infusions may be insufficient for pathogens with MIC ≥2 mg/L 3, 4.

Consider Broadening Coverage

If cultures reveal resistant organisms or clinical deterioration occurs:

• Add vancomycin (or linezolid/daptomycin) for MRSA coverage if not already included, particularly if there is purulent drainage, penetrating trauma, or systemic inflammatory response 1
• For necrotizing infection: Combine meropenem with vancomycin or linezolid to cover both MRSA and anaerobes 1

Antifungal Therapy Consideration

Add empiric amphotericin B (or lipid formulation) if fever persists through days 5-7 without identified bacterial source and neutrophil recovery is not imminent 1. This is critical because:

• Fungal infections (Candida, Aspergillus) occur in up to one-third of febrile patients not responding to 1 week of antibiotics 1
• Burn patients are at particularly high risk for invasive fungal infections 1
• Liposomal amphotericin B has superior safety compared to conventional formulations 1

Do not wait for definitive fungal diagnosis if clinical suspicion is high—obtain CT chest/abdomen, wound biopsies, and nasal endoscopy while initiating empiric therapy 1.

Duration and De-escalation

• Continue broad-spectrum therapy until source control is achieved, clinical improvement occurs, and patient is afebrile for 48-72 hours 1
• Typical duration: 7-10 days for most serious infections 1
• Longer courses needed for: slow clinical response, undrainable foci, bacteremia with S. aureus, or immunodeficiency 1
• Narrow antibiotics based on culture results as soon as susceptibilities are available 1

Critical Pitfalls to Avoid

• Do not continue inadequate twice-daily meropenem dosing—burn patients require three-times-daily administration 2, 5, 3
• Do not delay surgical debridement if necrotizing infection is suspected—surgery is the primary therapeutic modality 1
• Avoid routine antibiotic prophylaxis in burn patients, as this promotes multidrug-resistant organisms without proven benefit 1
• Do not assume fever is always infectious—consider drug fever, thrombophlebitis, or non-infectious inflammatory states after 5-7 days 1

Monitoring Parameters

• Daily wound examination and vital signs 1
• Repeat blood cultures if bacteremia was initially present 1
• Consider therapeutic drug monitoring for meropenem in critically ill burn patients to ensure adequate concentrations 1, 5
• Monitor for nephrotoxicity if aminoglycosides or polymyxins are added 1